|Systematic (IUPAC) name|
|Licence data||US FDA:|
|CAS Registry Number|
|Molecular mass||213.239 g/mol|
|(what is this?)|
Phenazopyridine is a chemical which, when excreted into the urine, has a local analgesic effect. It is often used to alleviate the pain, irritation, discomfort, or urgency caused by urinary tract infections, surgery, or injury to the urinary tract. Phenazopyridine was discovered by Bernhard Joos, the founder of Cilag.
Phenazopyridine is prescribed for its local analgesic effects on the urinary tract. It is sometimes used in conjunction with an antibiotic or other anti-infective medication at the beginning of treatment to help provide immediate symptomatic relief. Phenazopyridine does not treat infections or injury, it is only used for symptom relief. It is recommended that it be used for no longer than the first two days of antibacterial treatment as longer treatment may mask symptoms.
Phenazopyridine is also prescribed for other cases requiring relief from irritation or discomfort during urination. For example, it is often prescribed after the use of an in-dwelling Foley catheter, endoscopic (cystoscopy) procedures, or after urethral, prostate, or urinary bladder surgery which may result in irritation of the epithelial lining of the urinary tract.[dead link]
Phenazopyridine produces a vivid color change in urine, typically to a dark orange to reddish color. This effect is common and harmless, and indeed a key indicator of the presence of the drug in the body. Users of phenazopyridine are warned not to wear contact lenses, as phenazopyridine has been known to permanently discolor contact lenses and fabrics.
Phenazopyridine can also cause headaches, upset stomach (especially when not taken with food), or dizziness. Less frequently it can cause a pigment change in the skin or eyes, to a noticeable yellowish color. This is due to a depressed excretion via the kidneys causing a buildup of the drug in the skin, and normally indicates a need to discontinue usage. Other such side effects include fever, confusion, shortness of breath, skin rash, and swelling of the face, fingers, feet, or legs. Long-term use may cause yellowing of nails.
Phenazopyridine should be avoided by people with glucose-6-phosphate dehydrogenase deficiency, because it can cause hemolysis (destruction of red blood cells) due to oxidative stress. It has been reported to cause methemoglobinemia after overdose and even normal doses. In at least one case the patient had pre-existing low levels of methemoglobin reductase, which likely predisposed her to the condition. It has also been reported to cause sulfhemoglobinemia. 
Phenazopyridine is a type of azo dye. Other azo dyes, which were previously used in textiles, printing, and plastic manufacturing, have been implicated as carcinogenic agents that can cause bladder cancer. While phenazopyridine has never been shown to cause cancer in humans, evidence from animal models suggests that it is potentially carcinogenic.
This medication is pregnancy category B. This means that the drug has shown no adverse events in animal models, but no human trials have been conducted. It is not known if phenazopyridine is excreted in breast milk.
The full pharmacokinetic properties of phenazopyridine have not been determined. It has mostly been studied in animal models, but they may not be very representative of humans. Rat models have shown its half-life to be 7.35 hours, and 40% is metabolized hepatically (by the liver). It is an azo dye.
Mechanism of action
Phenazopyridine's mechanism of action is not well known, and only basic information on its interaction with the body is available. It is known that the chemical has a direct topical analgesic effect on the mucosa lining of the urinary tract. It is rapidly excreted by the kidneys directly into the urine. Hydroxylation is the major form of metabolism in humans, and the azo bond is usually not cleaved. On the order of 65% of an oral dose will be excreted directly into the urine chemically unchanged.
In addition to its generic form, phenazopyridine is distributed under the following brand names:
- Azo-Maximum Strength
- Pyridium Plus
- http://www.wcrx.com/pdfs/pi/pi_pyridium_plus.pdf[full citation needed]
- http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae0f0808-51ed-43b9-86a3-b947c42da89f[full citation needed]
- https://www.auanet.org/education/guidelines/ic-bladder-pain-syndrome.cfm[full citation needed]
- Wang, Alina; Nizran, Parminder; Malone, Michael; Riley, Timothy (September 2013). "Urinary Tract Infections". Primary Care - Clinics in Office Practice 40 (3): 693. doi:10.1016/j.pop.2013.06.005.
- http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682231.html[full citation needed]
- Amit, G; Halkin, A (15 December 1997). "Lemon-yellow nails and long-term phenazopyridine use". Annals of Internal Medicine (letter) 127 (12): 1137. doi:10.7326/0003-4819-127-12-199712150-00040. PMID 9412335.
- Tishler, M; Abramov, A (1983). "Phenazopyridine-induced hemolytic anemia in a patient with G6PD deficiency". Acta Haematol 70 (3): 208–9. doi:10.1159/000206727. PMID 6410650.
- Galun E, Oren R, Glikson M, Friedlander M, Heyman A (November 1987). "Phenazopyridine-induced hemolytic anemia in G-6-PD deficiency". Drug Intell Clin Pharm 21 (11): 921–2. PMID 3678069.
- Mercieca JE, Clarke MF, Phillips ME, Curtis JR (4 Sep 1982). "Acute hemolytic anaemia due to phenazopyridine hydrochloride in G-6-PD deficient subject". Lancet 2 (8297): 564. PMID 6125724.
- Frank JE (October 2005). "Diagnosis and management of G6PD deficiency". American Family Physician 72 (7): 1277–82. PMID 16225031.
- Jeffery WH, Zelicoff AP, Hardy WR. (February 1982). "Acquired methemoglobinemia and hemolytic anemia after usual doses of phenazopyridine". Drug Intell Clin Pharm 16 (2): 57–9. PMID 7075467.
- Daly JS, Hultquist DE, Rucknagel DL (August 1983). "Phenazopyridine induced methaemoglobinaemia associated with decreased activity of erythrocyte cytochrome b5 reductase". Journal of Medical Genetics 20 (4): 307–9. doi:10.1136/jmg.20.4.307. PMC 1049126. PMID 6620333.
- Halvorsen, SM; Dull, WL (September 1991). "Phenazopyridine-induced sulfhemoglobinemia: inadvertent rechallenge". American Journal of Medicine 91 (3): 315–7. doi:10.1016/0002-9343(91)90135-K. PMID 1892154.
- Kermani TA; Pislaru SV; Osborn TG (April 2009). "Acrocyanosis from phenazopyridine-induced sulfhemoglobinemia mistaken for Raynaud phenomenon". Journal of Clinical Rheumatology 15 (3): 127–9. doi:10.1097/RHU.0b013e31819db6db. PMID 19300288.
- Gopalachar AS; Bowie VL; Bharadwaj P (June 2005). "Phenazopyridine-induced sulfhemoglobinemia". Annals of Pharmacotherapy 39 (6): 1128–30. doi:10.1345/aph.1E557. PMID 15886294.
- Cystitis in Females~treatment at eMedicine
- Transitional Cell Carcinoma Imaging at eMedicine
- http://ntp.niehs.nih.gov/ntp/roc/twelfth/profiles/phenazopyridinehydrochloride.pdf#search=phenazopyridine | National Toxicology Program[full citation needed]
- Thomas BH, Whitehouse LW, Solomonraj G, Paul CJ (April 1990). "Excretion of phenazopyridine and its metabolites in the urine of humans, rats, mice, and guinea pigs". Journal of Pharm Sci 79 (4): 321–5. doi:10.1002/jps.2600790410. PMID 2352143.
- Jurima-Romet M, Thomas BH, Solomonraj G, Paul CJ, Huang H (March 1993). "Metabolism of phenazopyridine by isolated rat hepatocytes". Biopharm Drug Dispos 14 (2): 171–9. doi:10.1002/bdd.2510140208. PMID 8453026.
- "Phenazopyridine Hydrochloride". The American Society of Health-System Pharmacists. Retrieved June 30, 2015.
- Information about phenazopyridine from the US National Library of Medicine
- Interstitial Cystitis Association
- American Urological Association